ImageneBio, Inc.
IMA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001835579
In the last 90 days, ImageneBio, Inc. insiders filed 0 open-market purchases and 1 sale; 35 institutions reported holding it in 13F filings for Q2 2026, worth $36.8M in total; no superinvestor holds it.
13F holders, Q4 2022
Institutional positions in ImageneBio, Inc. as of Dec 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 34
- −8 vs. Q3 2022
- Shares held
- 26.3M
- +17.7K (+0.1%) vs. Q3 2022
- Total value
- $69.9M
- −$23.3M (−25.0%) vs. Q3 2022
- New holders
- 2
- 10 more added
- Sold out
- 10
- 9 more reduced
Compare with Q3 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting IMA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 35 | $36.8M |
| Q1 2026 | 39 | $26.8M |
| Q4 2025 | 41 | $32.9M |
| Q3 2025 | 33 | $38.3M |
| Q2 2025 | 41 | $42.6M |
| Q1 2025 | 46 | $41.9M |
| Q4 2024 | 53 | $52.0M |
| Q3 2024 | 57 | $49.1M |
| Q2 2024 | 70 | $47.9M |
| Q1 2024 | 57 | $42.7M |
| Q4 2023 | 54 | $63.8M |
| Q3 2023 | 58 | $141.6M |
| Q2 2023 | 52 | $204.7M |
| Q1 2023 | 39 | $86.2M |
| Q4 2022 | 34 | $69.9M |
| Q3 2022 | 42 | $93.2M |
| Q2 2022 | 46 | $118.7M |
| Q1 2022 | 48 | $167.8M |
| Q4 2021 | 49 | $343.6M |
| Q3 2021 | 39 | $271.8M |
| Q2 2021 | 42 | $293.2M |
| Q1 2021 | 27 | $538.5M |
Institutions, Q4 2022
Shares, value and share of portfolio for each institution holding ImageneBio, Inc.; share changes are against Q3 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Farther Finance Advisors, LLC | 50 | $133 | 0.00% | +50 | New |
| Wells Fargo & Company | 270 | $718 | 0.00% | +4+1.5% | Added |
| Citigroup Inc | 701 | $1.86K | 0.00% | +22+3.2% | Added |
| JPMorgan Chase & Co | 877 | $2.00K | 0.00% | −1,568−64.1% | Reduced |
| Baystate Wealth Management LLC | 2,999 | $8.00K | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 3,669 | $9.76K | 0.00% | −47,846−92.9% | Reduced |
| Bank of America Corp | 9,109 | $24.2K | 0.00% | +8,492+1,376.3% | Added |
| Millennium Management LLC | 10,199 | $27.0K | 0.00% | +10,199 | New |
| Charles Schwab Investment Management Inc | 12,066 | $32.1K | 0.00% | 00.0% | Unchanged |
| Acadian Asset Management LLC | 13,301 | $34.0K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 13,918 | $37.0K | 0.00% | +10,076+262.3% | Added |
| Ergoteles LLC | 17,606 | $46.8K | 0.00% | −83,034−82.5% | Reduced |
| Northern Trust Corp | 27,119 | $72.1K | 0.00% | −115−0.4% | Reduced |
| Dimensional Fund Advisors LP | 28,682 | $77.0K | 0.00% | +3,537+14.1% | Added |
| Cornercap Investment Counsel Inc | 29,465 | $78.4K | 0.01% | 00.0% | Unchanged |
| State Street Corp | 50,753 | $135.0K | 0.00% | +19,200+60.8% | Added |
| Bridgeway Capital Management, LLC | 89,650 | $238.5K | 0.01% | −2,150−2.3% | Reduced |
| Ensign Peak Advisors, Inc | 90,310 | $240.2K | 0.00% | 00.0% | Unchanged |
| DAFNA Capital Management LLC | 122,517 | $325.9K | 0.09% | 00.0% | Unchanged |
| Oasis Management Co Ltd. | 140,000 | $372.4K | 0.08% | 00.0% | Unchanged |
| Barclays PLC | 199,403 | $530.4K | 0.00% | −1,824−0.9% | Reduced |
| Geode Capital Management, LLC | 236,434 | $628.0K | 0.00% | −514−0.2% | Reduced |
| BlackRock Inc. | 305,416 | $812.4K | 0.00% | −196,736−39.2% | Reduced |
| Laurion Capital Management LP | 529,000 | $1.41M | 0.04% | 00.0% | Unchanged |
| Vanguard Group Inc | 979,517 | $2.61M | 0.00% | +514+0.1% | Added |
| Artal Group S.A. | 1,549,513 | $4.12M | 0.24% | 00.0% | Unchanged |
| Verition Fund Management LLC | 1,580,375 | $4.20M | 0.08% | +281,120+21.6% | Added |
| CHI Advisors LLC | 1,637,372 | $4.36M | 1.16% | +423,068+34.8% | Added |
| Citadel Advisors LLC | 2,155,134 | $5.73M | 0.01% | −3,345−0.2% | Reduced |
| Omega Fund Management, LLC | 2,249,123 | $5.98M | 2.02% | 00.0% | Unchanged |
| BVF Inc | 2,503,071 | $6.66M | 0.28% | 00.0% | Unchanged |
| OrbiMed Advisors LLC | 2,933,941 | $7.80M | 0.15% | 00.0% | Unchanged |
| FMR LLC | 3,724,575 | $9.91M | 0.00% | +1,198,372+47.4% | Added |
| Atlas Venture Life Science Advisors, LLC | 5,018,178 | $13.3M | 1.61% | 00.0% | Unchanged |
| Point72 Asset Management, L.P. | 0 | $0 | 0.00% | −1,343,496−100.0% | Sold out |
| HealthCor Management, L.P. | 0 | $0 | 0.00% | −220,082−100.0% | Sold out |
| Qube Research & Technologies Ltd | 0 | $0 | 0.00% | −19,201−100.0% | Sold out |
| Goldman Sachs Group Inc | 0 | $0 | 0.00% | −12,428−100.0% | Sold out |
| Zurcher Kantonalbank (Zurich Cantonalbank) | 0 | $0 | 0.00% | −2,472−100.0% | Sold out |
| BNP Paribas Arbitrage, SA | 0 | $0 | 0.00% | −976−100.0% | Sold out |
| MUFG Americas Holdings Corp | 0 | $0 | 0.00% | −450−100.0% | Sold out |
| Royal Bank of Canada | 0 | $0 | 0.00% | −231−100.0% | Sold out |
| China Universal Asset Management Co., Ltd. | 0 | $0 | 0.00% | −340−100.0% | Sold out |
| Daiwa Securities Group Inc. | 0 | $0 | 0.00% | −105−100.0% | Sold out |